In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Sacubitril valsartan, a multicentric experience

Session Poster Session 3

Speaker Francisco Javier Cortes

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : FJ Cortes (Seville,ES), DF Arroyo Monino (Seville,ES), MI Fernandez Valenzuela (Seville,ES), MI Rivadeneira Ruiz (Seville,ES), P Ruiz Garcia (Seville,ES), M Chaparro Munoz (Seville,ES), AJ Castro Fernandez (Seville,ES), A Recio Mayoral (Seville,ES)

Authors:
FJ Cortes1 , DF Arroyo Monino1 , MI Fernandez Valenzuela1 , MI Rivadeneira Ruiz1 , P Ruiz Garcia1 , M Chaparro Munoz1 , AJ Castro Fernandez1 , A Recio Mayoral1 , 1Virgen Macarena University Hospital - Seville - Spain ,

Citation:

Introduction: In the years following the publication of PARADIGM-HF trial in 2014, a growing evidence supports the safety and efficacy of sacubitril/valsartan in patients with HFrEF. The purpose of this study is to analyse the impact of sacubitril/valsartan on real world heart failure cohort.

Material and methods: We performed a prospective observational study with patients with HFrEF pick out in outpatient clinic, who started treatment with Sacubitril/Valsartan between January 2016-January 2018. We analysed their baseline characteristics and the functional class, renal function and drug tolerance in one year follow-up.

Results: 336 patients were included during the observed time period, with a mean age of 67,55 ± 10,93 years, being 24,5% female. The main basaline ejection fraction was 30,1 ± 6,8. The main cause of heart failure was ischemic heart disease (42,7%). Initially, the majority were in FC II-III (87%). In a review at 12 months follow-up, ARNI was at low doses in 23%, at medium doses 32% and the rest at high doses. Only a small proportion of patients (11%) have been down-titrated after achieving the maximal target dose of sacubitril/valsartan by sintomatic hipotension. Concerning analytical parameters, we did not find significant differences in renal function or in potassium levels during follow-up.

Conclusions: The treatment with sacubitril/valsartan in a group of patients in real-life was generally well tolerated with a significant decrease in blood pressure, being able to optimize the dose of sacubitril/valsartan. It was also related to improvement in the functional class without find significant differences in renal function during follow-up.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are